-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on InflaRx, Maintains $6 Price Target

Benzinga·12/30/2025 15:35:47
Listen to the news
HC Wainwright & Co. analyst Matthew Keller reiterates InflaRx (NASDAQ:IFRX) with a Buy and maintains $6 price target.